Source:http://linkedlifedata.com/resource/pubmed/id/15647409
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-1-13
|
| pubmed:abstractText |
The pharmacokinetics of piperacillin/tazobactam (4 g/0.5 g every 6 or 8 hours, by 20-minute intravenous infusion) were studied in 14 patients with acute renal failure who underwent continuous venovenous hemofiltration with AN69 membranes. Patients were grouped according to severity (CL(CR) < or =10 mL/min, 10 < CL(CR) < or =50 mL/min, and CL(CR) > 50 mL/min). A noncompartmental analysis was performed. The sieving coefficient (0.78 +/- 0.28) was similar to the unbound fraction (0.65 +/- 0.24) for tazobactam, but it was significantly different (0.34 +/- 0.25) from the unbound fraction (0.78 +/- 0.14) for piperacillin. Extracorporeal clearance was 37.0% +/- 28.8%, 12.7% +/- 12.6%, and 2.8% +/- 3.2% for piperacillin in each group and 62.5% +/- 44.9%, 35.4% +/- 17.0%, and 13.1% +/- 8.0% for tazobactam. No patients presented tazobactam accumulation. In patients with CL(CR) < 50 mL/min, t(%)ss >MIC90 values were 100% for a panel of 19 pathogens, but in those with CL(CR) > 50 mL/min, t(%)ss >MIC90 indexes were 55.5% and 16.6% for pathogens with MIC90 values of 32 and 64. The extracorporeal clearance of piperacillin/tazobactam is clinically significant in patients with CL(CR) > 50 mL/min, in which the risk of underdosing and clinical failure is important and extra doses are required.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0091-2700
|
| pubmed:author |
pubmed-author:ArzuagaAlazneA,
pubmed-author:CanutAndrésA,
pubmed-author:CorralEstherE,
pubmed-author:FonsecaFernandoF,
pubmed-author:GascónAlicia RAR,
pubmed-author:IslaArantxazuA,
pubmed-author:MaynarJavierJ,
pubmed-author:PedrazJosé LuisJL,
pubmed-author:RelloJordiJ,
pubmed-author:Sánchez-IzquierdoJosé AngelJA
|
| pubmed:issnType |
Print
|
| pubmed:volume |
45
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
168-76
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15647409-Aged,
pubmed-meshheading:15647409-Area Under Curve,
pubmed-meshheading:15647409-Chromatography, High Pressure Liquid,
pubmed-meshheading:15647409-Drug Therapy, Combination,
pubmed-meshheading:15647409-Female,
pubmed-meshheading:15647409-Half-Life,
pubmed-meshheading:15647409-Hemofiltration,
pubmed-meshheading:15647409-Humans,
pubmed-meshheading:15647409-Inpatients,
pubmed-meshheading:15647409-Intensive Care,
pubmed-meshheading:15647409-Intensive Care Units,
pubmed-meshheading:15647409-Kidney,
pubmed-meshheading:15647409-Kidney Failure, Chronic,
pubmed-meshheading:15647409-Male,
pubmed-meshheading:15647409-Microbial Sensitivity Tests,
pubmed-meshheading:15647409-Middle Aged,
pubmed-meshheading:15647409-Penicillanic Acid,
pubmed-meshheading:15647409-Piperacillin,
pubmed-meshheading:15647409-Time Factors
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration.
|
| pubmed:affiliation |
Laboratorio de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Paseo de la Universidad no. 7, 01006 Vitoria-Gasteiz, Spain.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|